>ACROBiosystems Enables the Development of New Tools to Fight SARS-CoV-2
In December, 2019, a novel coronavirus hit the human population and caused a worldwide pandemic from which we have yet to recover. Even considering that the current vaccines will be successful, we are still in need of more tools and novel approaches to effectively fight back the evolving SARS-CoV-2 contagion.
For this reason, ACROBiosystems is supporting, teaming, and coordinating efforts with prominent scientists and institutions from around the world to help find novel ways to protect people from SARS-CoV-2 infective attacks; such as with the recent collaboration established with Professor Michael Wallach of the University of Technology, Sydney, Australia. and the Director of the Centre for Innovative Medical Research.
Prof. Wallach, a renowned expert in infectious diseases & vaccines, has over 30 years of experience in basic and applied molecular parasitology & virology with a background in both academic and industrial science. He is also the Director of SPARK Oceania, which is part of the SPARK Global consortium, which promotes medical research that benefits patients through seed funding, innovative ideas and a program of mentoring and support for aspiring researchers.
Prof Wallach is working on ground breaking methods to prevent COVID-19 infection by using antibodies against the existing and emerging SARS-CoV-2 variants (such as UK and South African strains) that can easily be obtained from chicken eggs and formulated into lozenges to directly protect the nasopharyngeal tract as a first line of defense against COVID. This work is being carried out in collaboration with Camas Inc. Animal Agriculture Company, Le Center, Minnesota, USA. Camas has a great deal of experience in coronaviruses that affect veterinary medicine.
The many advantages of this approach include the fact that chicken antibodies can be rapidly mass produced at a low cost anywhere in the world, and that lozenges conveniently serve as a passive auto-administrated blockade that catches the virus before it enters or exits the body by immobilizing SARS-CoV-2 and inhibiting viral binding to the ACE2 receptor. This approach can be combined with nasal formulations that block viral entry as well.
Nasopharyngeal immunotherapies have already successfully been implemented to fight Rhinosinusitis, Respiratory Syncytial Virus (RSV), Influenza, and Allergy disorders by directly employing many types of biologics and drugs as the active therapeutic agents. The proven versatility of the nasal immunotherapies offers interesting new opportunities like the one being explored by Professor David L. Brody at NIH’s National Institute of Neurological Disorders and Stroke (NINDS), where his team generated llama nanobodies against the SARS-CoV-2 spike protein utilizing ACROBiosystems products as a method to prevent infections.
The beauty of nanobodies is that they are small 12-15 kDa single-domain antibody fragments that show superior properties such as chemical stability, high affinity to a broad spectrum of epitopes, low immunogenicity, ease of generation and initially effective in an infection relevant SARS-CoV-2 virus model as proven by Dr. Brody, suggesting that the nanobody could remain effective after inhalation.
These results exemplify how novel biologic-based therapeutic applications can effectively be developed utilizing current available antigens and antibodies from the ACROBiosystems catalogue.
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostics. The team has established long-term collaborations with big pharms, such as Pfizer, Novartis, and Johnson & Johnson, and well-known academic institutes.
To fight against COVID-19, ACROBiosystems has developed high-quality super stable trimeric S protein, S RBD, S1, S2, and N proteins, COVID-19 variants, paired antibodies with outstanding sensitivity verified by inactivated virus samples and featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection to accelerate the vaccine development.
The Centre for Innovative Medical Research
The Centre for Innovative Medical Research is located in Sydney, Australia and was established to accelerate international collaboration for ideation, research, development, and commercialisation of scientific breakthroughs for the benefit of humankind.
The Stanford SPARK program was established in 2006 to advance academic biomedical research discoveries into promising new treatments for patients. SPARK bridges the gap between discovery and drug treatment through a unique partnership between university and industry experts.
This web search service is supported by Google Inc.